Decision support · not medical adviceDr Lisa M. Guirguis8:30 · 2825 Capitol2026-07-22
Dawn — One-pager for breast surgeon consult
Surgeon: Lisa M. Guirguis, M.D. (Sutter Medical Group · breast surgical oncology) ·
appointment 8:30 AM · 2825 Capitol Ave, Sacramento (clinic 2800 L St #300 · 916-733-9660).
Preferred first protocol: close observation / risk-adapted monitoring first, with
continuation of individualized HRT when absolute risks support it.
Pathology: Stage 0 DCIS, right UOQ · intermediate nuclear grade · solid + comedonecrosis ·
ER ~90% strong+ · PR ~60% strong+ · no invasive ca. on core · accession DPS-26-17107
(DPMG). Hormones: systemic HRT (E±P±T) in active use — confirm regimen with patient.
Full Guirguis credentials brief: /dawn-surgeon-guirguis.html.
1. Framing we want in the room
DCIS is not invasive breast cancer. Many lesions never progress; population overtreatment is a recognized problem (screening-era rise in DCIS without matching mortality drop).
Goal today: shared decision using absolute risks (events per 100 women over 5–10 years), not fear-based relative percentages alone.
Preferred sequence: (A) confirm extent & eligibility for observation-first or short deferred intervention with intensive imaging; (B) preserve systemic HRT unless clear absolute harm is quantified; (C) only then escalate to surgery ± radiation ± endocrine therapy if risk is not acceptable to patient/surgeon.
2. Observation-first — evidence arguments
Why observation is a legitimate first conversation
Biology: DCIS is confined to ducts on definition. Core biopsy found no invasive carcinoma. The clinical problem is risk of progression / occult invasion, not proven metastasis.
Trials exist for low-risk DCIS: COMET (NCT02926911) and related programs test active monitoring vs guideline care for selected low-risk DCIS (typically low grade, ER+, no comedonecrosis). Early/companion literature frames surgery omission as a live research question for low-risk disease (e.g. JAMA discourse 2024–25 on abandoning surgery for low-risk DCIS).
Overtreatment concern: Standard paths (excision ± RT ± endocrine) improve local control for many, but for some women the lifetime invasive risk may not justify all side effects. Asking for a risk-adapted path is standard good care, not denial.
Honesty about this pathology: Intermediate grade + comedonecrosis usually excluded pure COMET-style surveillance. That does not force mastectomy; it means we ask for the least invasive path that still meets safety thresholds (second path review, MRI extent, possible short interval re-imaging, endocrine discussion, trial referral if any, second opinion at a center open to de-escalation).
Key ask: “Given intermediate grade + comedonecrosis, am I trial-ineligible for pure active monitoring—and if so, what is the minimal next step that still lets us avoid overtreatment?”
3. Maintain HRT — evidence arguments
Why continuing hormones can be reasonable
Not all HRT is the same. WHI long-term data: estrogen + progestin raised breast cancer incidence; estrogen-alone (after hysterectomy) was associated with lower breast cancer incidence and breast-cancer mortality in long follow-up (~23% fewer diagnoses; larger relative drop in BC deaths in published WHI analyses). Regimen matters more than the word “HRT.”
Absolute risks are modest and age-dependent. Combination therapy risk is duration-related; absolute excess events are often low per year, especially under 60 / within 10 years of menopause (NAMS and WHI re-analyses emphasize timing).
Stopping HRT has real costs: vasomotor symptoms, sleep, bone density / fracture risk, genitourinary health, quality of life, and for some younger postmenopausal women, cardiovascular tradeoffs when therapy is withdrawn abruptly.
“Fuel for DCIS” is a hypothesis, not a settled absolute mandate to stop. ER+/PR+ cells can respond to estrogen signaling—so the team should quantify: absolute change in ipsilateral invasive risk if hormones continue vs stop for 6–12 months, versus absolute harm from abrupt cessation. Demand numbers, not slogans.
If systemic therapy is needed later, endocrine options (tamoxifen / AI) are separate from menopausal HRT and can be planned after local strategy is clear—without permanently abandoning symptom control or bone protection without a plan.
Key ask: “What is my absolute 5–10 year invasive risk if I continue current HRT vs stop—and what non-hormonal supports do you recommend if we taper?”
4. Preferred protocol language (copy into the visit)
Observation-first: “I understand intermediate grade and comedonecrosis raise concern. I want the most conservative safe path first: confirm no occult invasion strategy, imaging extent (MRI if useful), second path review if needed, and only then surgery. Can we document why pure active surveillance is or is not appropriate for me in absolute-risk terms?”
HRT: “I am on HRT for quality of life and systemic health. Please distinguish estrogen-alone vs combination risks for me personally. I prefer to maintain therapy unless you can show a clear absolute-risk reason to stop, and if we stop, I need a written plan for symptoms and bone health.”
Precision gates: “On excision or if we defer: HER2 status if not scored; margins policy; whether DCISionRT / genomic tools would change radiation; germline panel if family history warrants.”
5. Questions we want answered today (absolute numbers)
Upgrade-to-invasive risk at excision for this core pathology (events per 100).
Am I eligible for any observation / delayed-intervention protocol? If no, what exact feature blocks it?
10-year ipsilateral invasive risk: observation vs lumpectomy alone vs lumpectomy+RT vs mastectomy.
Is pre-op MRI recommended for extent given density?
Continue vs hold current HRT: absolute risk difference over 5 years.
If hold: for how long, and who restarts (PCP vs oncology)?
Endocrine therapy later: when does it become relevant if we observe first?
Would you support a second opinion at a de-escalation / COMET-experienced center?
6. What we are not asking you to do
Ignore comedonecrosis or pretend this is trial-identical low-risk DCIS.
Promise zero risk with observation—there is no zero-risk path.
Use Estrogen Matters / advocacy literature as a prescription; it is risk-literacy context for shared decisions.